Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   24/12/2025
31,74 USD (+0,63%)
(+0,63%)   24/12/2025

24 december 2025 · S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive · Persbericht

19 december 2025 · Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® · Persbericht

12 december 2025 · Teva Releases Q4 2025 Aide Memoire · Persbericht

12 december 2025 · Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 · Persbericht

9 december 2025 · Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults · Persbericht

26 november 2025 · Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva® · Persbericht

25 november 2025 · Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® · Persbericht

21 november 2025 · Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December · Persbericht

19 november 2025 · Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges · Persbericht

8 november 2025 · AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living · Persbericht

5 november 2025 · Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS · Persbericht

3 november 2025 · Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis · Persbericht

31 oktober 2025 · Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November · Persbericht

21 oktober 2025 · Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe · Persbericht

20 oktober 2025 · Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe · Persbericht

10 oktober 2025 · FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder · Persbericht

1 oktober 2025 · Europese Commissie opent mededingingsonderzoek naar griepvaccins bij Sanofi · Bolero.be

Sanofi bevestigt dat de Europese mededingingsautoriteiten invallen hebben gedaan in kantoren in Frankrijk en Duitsland. De Europese Commissie onderzoekt mogelijke misleidende communicatie over concurrenten in de griepvaccinmarkt,...

25 september 2025 · Teva Releases Q3 2025 Aide Memoire · Persbericht

25 september 2025 · Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 · Persbericht

21 september 2025 · Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction · Persbericht

Mijn selecties